Skip to main content
. 2021 Apr 8;22(8):3867. doi: 10.3390/ijms22083867

Figure 3.

Figure 3

Kaplan–Meier curves showing significantly prolonged progression-free survival (PFS) in patients who received neoadjuvant and adjuvant pembrolizumab (median PFS = 72.5 days, red curve) compared to patients who received pembrolizumab only in the adjuvant setting (blue curve) (median PFS= 99.5 days, two-sided p = 0.03 by log-rank test). Reprinted with permission from ref. [49]. Copyright 2019 Springer Nature America, Inc.